Abstract

Infliximab has been widely used in paediatric Crohn's disease, mainly in luminal and fistulous disease refractory to standard treatment and for extraintestinal manifestations. Moreover, there is growing experience with its use in refractory ulcerative colitis. Infliximab has shown similar efficacy and safety in children as in adult population. It is postulated that its early use in paediatric inflammatory bowel disease, as a bridging treatment until the onset of action of other immunomodulators, could reduce the use of steroids and change the natural history of the disease as well. The effect of infliximab on mucosal healing could also contribute to the normal growth and sexual maturation in these patients.

Introduction

The onset of inflammatory bowel disease (IBD) in paediatric age is associated to a high rate of complications, sometimes more severe than those occurring in adult patients. In children and adolescents, the chronic maintenance of mucosal inflammation (either with or without symptoms) has deleterious effects upon their growth and development, and increases the likelihood of a torpid evolution of the disease itself. In the last years, there is a growing trend to prefer therapies able to achieve mucosal healing – enteral nutrition, 1 , 2 azathioprine, infliximab 3 – rather than treatments that merely ameliorate symptoms with no improvement in mucosal damage, such as steroids 4 or mesalazine.

Protracted mucosal inflammation should result in a greater probability of irreversible damage. Therefore, the early use of able to heal the mucosa appears to be of utmost importance. In children with Crohn's disease, the response to infliximab appears to be better and persist for a longer time when this biological agent is used earlier in the course of the disease. 57 On the other hand, adults receiving infliximab therapy associated to azathioprine have long-term (two years) rate of mucosal healing as high as 75%, in comparison to only 25% in those patients receiving classical treatment with steroids. 8 These data are viewed as an indirect evidence that early “aggressive” therapy may result in a more complete remission, thus avoiding the need for other therapies. 9 Indeed, maintained mucosal healing with infliximab therapy has been reported to be associated to lower complication and hospitalisation rates in adult Crohn's disease patients, 10 thus suggesting that this agent would be able to alter the natural course of the disease.

In the present article, available data on the efficacy and safety of infliximab in paediatric Crohn's disease and ulcerative colitis are reviewed. In addition, the impact of this therapy on the catch-up growth of these patients is also discussed.

Efficacy of infliximab in paediatric Crohn's disease

In spite that the first reported IBD patient treated with the anti-tumour necrosis factor (TNF) monoclonal antibody infliximab – in 1993 – was a 13-year-old girl suffering from severe Crohn's disease, 11 the first trial of the use of this agent in paediatric Crohn's disease patients was published as late as in 2000. 6 In fact, most published papers on the paediatric use of infliximab are retrospective and uncontrolled series. Most of these studies use the paediatric Crohn's disease activity index (PCDAI), a validated index for children and adolescents that, in contrast to the adult Crohn's disease activity index (CDAI) includes parameters of growth retardation as well as laboratory markers of inflammation, rather than subjective symptoms. 12 , 13 PCDAI scores from 0 to 100 points. Scoring ≤ 10 points are considered as inactive disease, mild disease scores from 11 to 30 points whereas scoring > 30 points denote moderate/severe disease. In most papers, clinical remission is defined as a PCDAI ≤ 10, and clinical response as a decrease in PCDAI of at least 15 points (and below 30 points) from pre-treatment value.

As in adult patients, paediatric use of infliximab has been mostly restricted to patients with moderate/severe or fistulising disease who were refractory or dependent to steroid and who also failed to respond to traditional immunomodulators. However, the possibility of using this agent as a bridging therapy to long-term immunomodulatory maintenance therapy or even as a first line treatment to avoid the sue of steroids should be considered, particularly in children and adolescents. In this respect, it has been suggested that infliximab would be more potent in children than in adults, since many paediatric patients respond well to an early short-scheduled administration of the agent, remaining thereafter in remission for years. 14

There are data suggesting that the effectiveness of infliximab in children and adolescent depends on how early is this agent used. Kugathasan et al. 6 prospectively assessed the short- and long-term response to a single infusion of infliximab in 15 paediatric patients (mean age 12.8 years, range 6–18) with refractory Crohn's disease. A rapid and dramatic response was obtained in 14 out of 15 patients. Of these, six patients had an “early” (< 2 years) and eight had a “late” (> 2 years) disease. At 10th week, 10 of these patients remained and remission without differences between those with “early” or “late” disease. However, at week 32, all patients with “late” disease had lost their response to infliximab, as compared to those with “early” disease in whom remission was maintained in 3/6 patients at week 52. In a similar paper, Lionetti et al. 5 report on the outcome of 22 patients with refractory and/or fistulising Crohn's disease treated with infliximab “on demand”. Six and 16 patients were classified as having “early” (< 1 year), and “late” (> 1 year) disease, respectively. After 16 weeks of therapy the PCDAI was significantly lower in those patients with “early” than in those with “late” disease. Moreover, fistulising disease also had a better evolution in patients with “early” disease: 5/6 in this group had complete fistula closure, as compared to 2/7 in the “late” disease group. These data suggest that therapeutic response of infliximab is more sustained in patients with shorter lived disease, so that the early use of infliximab in paediatric Crohn's disease might be of benefit.

Very recently the REACH trial has been published. 15 This is an open, multicentric and randomized trial designed to assess the efficacy and safety of infliximab in paediatric patients suffering from moderate-to-severe Crohn's disease refractory to steroids and/or immunomodulators. One-hundred and twelve patients (mean age: 13 years, range 6–17) with Crohn's disease diagnosed at least 3 months before, PCDAI higher than 30, and at least 8 weeks on immunomodulators, were treated with three induction infusions (5 mg/Kg each) of infliximab at weeks 0, 2 and 6. Those patients who responded to the induction schedule were then randomized (1:1) at week 10 to receive maintenance therapy every 8 weeks (q8, n = 52) or every 12 weeks (q12, n = 51) at the same dose, until week 46. The clinical response/remission was evaluated at week 54. Patients who lost response (PCDAI > 30 or 15 or more points increase above the week 10 value) were eligible to cross over one time during the study to receive treatment more frequently and/or at a higher dose, depending on the length of time between the previous infusion and the loss of response. If response was lost prior to 8 weeks from the previous infliximab infusion, for both q8 and q12 groups, patients were eligible to cross over to infliximab 10 mg/kg every 8 weeks. Patients of the group q12 who lost response within the period from week 8 to week 12 following the previous infusion were eligible to cross over to infliximab 5 mg/kg every 8 weeks. Assessment of clinical efficacy was made on an intention-to-treat basis.

At week 10, the clinical response rate was 88.4% (91/112), and clinical remission occurred in 58.9% of the cases (66/112). At week 54, response and remission rates were 63.5% (33/52) and 55.8% (29/52) in the q8 groups, and 33,3% (17/51) and 23.5% (12/51) in the q12 group ( p = 0.002, and p < 0.001, respectively) ( Fig. 1 ). 15 For this analysis, those patients who crossed over or escalated dose were considered as non-responders. About 50% of patients in the group q12 lost response (25/51) vs. only 19% in the group q8 (10/52). Seventy-five per cent of patients who crossed over or escalated dose re-gained response. 15

The proportion of paediatric patients achieving clinical response or remission at week 10 in the REACH trial was higher that those observed in adults in the ACCENT I trial 16 ( Fig. 2 ). Some characteristics of both trials could account for these differences: a) All patients in the REACH trial were on immunomodulators for at least 8 weeks, whereas only about 27% fulfilled this criterion in the ACCENT I trial, b) In the paediatric study smoking consumption is not relevant (although there is no evaluation of passive smoking), and c) the mean duration of the disease was shorter in the REACH study (1,6 vs. 7.0 years).

Taken together, the results of the REACH trial suggest that the clinical response to infliximab, in paediatric patients with moderate-to-severe Crohn's disease unresponsive to conventional therapies, is quite similar to that in adult patients. Infliximab is effective for both inducing and maintaining remission or response, and for sparing steroids as well. Maintenance infusions every 8 weeks appear superior than an every 12-week schedule.

Although there are no conclusive data, one can speculate with the possibility of using infliximab as first line therapy, at the onset of the disease, in children. It is conceivable that the early use of infliximab, with its ability for healing mucosal damage, might be a “curative” treatment able to revert the chronic inflammatory reaction in the bowel before it auto-perpetuates. 17

Efficacy of infliximab in paediatric ulcerative colitis

The experience with infliximab in the treatment of paediatric patients with ulcerative colitis is quite limited, since all published studies are retrospective, non-controlled, and include a small number of patients. 1826 Moreover, there is no homogeneity either in the inclusion criteria for treatment (although most patients had a steroid-refractory or steroid-dependent moderate-to-severe disease), or the definition of short- and long-term response. There is also a lack of consensus regarding the induction and maintenance dose as well as in the concomitant use of immunomodulators.

The recently published ACT1 and ACT2 trials show a clear benefit of infliximab in adult patients with moderate/severe ulcerative colitis. 27 The clinical response at 8 weeks ranges from 29% to 37% in the placebo groups as compared to 64%–69% in the therapeutic groups ( p < 0.001). 27 At weeks 30 and 54, the clinical response was still better with infliximab than with placebo. A recent systematic review on the efficacy and safety of infliximab in ulcerative colitis includes 92 children ( Table 1 ). The short-term (mean 2.2 weeks) response and remission rates were 75% (95%CI: 64%–83%), and 63% (95%CI: 47%–76%), respectively. Long-term response (mean 7.9 months) reached 43% (95%CI: 33%–55%). Long-term remission was only assessed in one series of only 14 patients 24 ( Table 1 ).

As in Crohn's disease, it would be nice to identify predictive factors for response to infliximab. In a recent study, Ferrante et al. 29 assessed the response to infliximab in 100 adult patients with ulcerative colitis (84 patients received a single dose of 5 mg/kg, and the remaining 37 cases were treated with a three-dose induction schedule). Sixty-five per cent of patients achieved a short-term response (either complete or partial) as evaluated at week 4 in those treated with a single dose, or at week 10 in those treated with three induction doses. Response was worse in those patients bearing a serotype pANCA(+)/ASCA(−), and in older patients as well. 29 The age at diagnosis, the duration of the disease, the concomitant use of immunomodulators, and the therapeutic schedule used did not influence the short-term response to infliximab. 29

In spite of the limitations inherent to the above-mentioned paediatric series, one can speculate that infliximab would be particularly useful in acute steroid-refractory ulcerative colitis receiving concomitant immunomodulator treatment than in patients with steroid-dependent disease 18 , 24 ( Table 1 ).

The optimal duration of infliximab therapy in ulcerative colitis is not defined yet. Fanjiang et al. 25 recommend to maintain the treatment every 8 weeks for one year, and then start with a progressive weaning, according to the clinical response, increasing the time between doses to 10 and 12 weeks, until discontinuation. Following this policy, with a mean follow-up of 10 months (range: 1–52) after the last infliximab infusion, remission was maintained in all patients who were able to discontinue the drug (80% of the initial responders). 25 At long-term, 75% of patients with either steroid-resistant or acute disease without steroid-dependence were able to maintain the clinical response, as compared to only 25% of steroid-dependent patients. 25 All patients received treatment with immunomodulators both during and after infliximab therapy. These results are in agreement with those obtained in adult ulcerative colitis, where only 33% of steroid-dependent patients improved, as compared to 83% in non-steroid-dependent cases. 30

In summary, on the light of published data, it is conceivable that infliximab might be as effective in paediatric as in adult patients with ulcerative colitis, but large randomized controlled trials are needed in this particular group of patients to confirm such a suggestion.

Safety of infliximab in paediatric IBD

Reactions to infusion

The reported frequency of both acute and delayed reactions to infusion of infliximab in children with IBD is similar to that reported in adult patients. A review of the paediatric literature yields a rate of reactions to infusion of about 17%, most of them being acute reactions (93%) defined as any event occurring during or in the immediate 2 h following the infusion. This frequency drops dramatically if one only takes into account those reactions needing medical care. 31 Most reactions to the infusion occur after the second or third dose of infliximab. Predictive factors for reactions to infusion in children include a) female gender, b) previous history of reactions to infusion, and c) less than four months on immunomodulator therapy. 31

Most acute reactions to the infusion are easy to manage either with antihistaminic drugs or steroids. 32 Chronic (i.e. serum sickness-like) reactions require high-dose steroid therapy for 4–7 days, as well as prophylaxis with steroids (48 h before 5–7 days after the infusion) in further infusions.

Prophylactic pre-medication before infusions allows to decrease the frequency of reactions to infusion in those patients who had developed them previously. It has been also suggested that its use before the first infliximab infusion might prevent the development of these reactions. In adult patients, the number of reactions to infusion diminish with the concomitant use of immunomodulators, as well as with the scheduled use of infliximab (every 8 weeks) rather than administering it on demand. To our knowledge, there is only one study addressing this issue in paediatric patients with an adequate sample size ( n = 243). 33 In this study, no benefit could be demonstrated from either administering pre-medication from the first infusion, using concomitant immunomodulators or administering infliximab on a scheduled sequence, in terms of reduction of the number of reactions to the infusion. 33 It is important to note that 7% of these reactions occurred after the first infliximab infusion, suggesting that a placebo effect could account for some of these events.

Infections

As in adult patients, infections associated to the use of infliximab have been reported in paediatric patients. Non-severe respiratory infections are the most common infectious complications associated to infliximab use in children, but cases of herpes zoster, tinea corporis , catheter sepsis, meningitis due to Listeria spp., or a fatal case due to sepsis in a malnourished and leukopenic patient undergoing multiple surgical procedures, have been reported. To date, there are no reports of tuberculosis or hepatitis B reactivation in paediatric patients treated with infliximab. However, a complete tuberculosis work-up – including anamnesis, Mantoux test and X-ray film of the thorax – as well as serologic test for hepatitis B virus must be performed in any patient candidate to be treated with infliximab.

Neoplasia

The long-term adverse consequences of the use of infliximab still are a controversial issue. The development of neoplastic disease is a major concern for doctors using this agent, mainly in paediatric patients. Apparently, there is no increased risk for developing lymphomas in patients with IBD, but the role of conventional immunomodulators in the development of these neoplasms is a matter of debate.

Hepatosplenic T-cell lymphoma (HSTCL) is a rare neoplasm with about 100 cases reported in world literature. However, eight of them have been described associated to the use of infliximab 34 , 35 suggesting an increasing risk of this kind of lymphoma in patients treated with this biological agent, particularly young individuals (all reported patients were younger than 31). Nevertheless a primary or unique pathogenic link between TNF blockade and the development of HSTCL in IBD patients cannot be established, since all reported cases were on concomitant azathioprine or 6-mercaptopurine therapy, and there are some report of HSTCL in patients treated only with these traditional immunomodulators. 36 , 37

Some experts in the management of IBD – particularly those dealing with paediatric disease – recommend not to use immunomodulators concomitantly to infliximab for more than six months, on the basis of recent studies which suggest that concomitant immunomodulatory therapy adds little benefit to the long-term maintenance therapy with infliximab, in terms of prevention of relapse. 38 , 39

Congestive heart failure

It is well known that infliximab can worsen congestive heart failure. Recently, the preliminary results of a study assessing the heart function (by means of electro- and echocardiogram) during infliximab therapy, in twelve paediatric IBD patients (9 Crohn's disease, 3 ulcerative colitis), have been published. 40 Seven out of 12 patients showed cardiac disturbances consisting of dilation of the cardiac cavities (5 cases) and septal hypertrophy (2 cases), with a direct correlation between the length of Q–T interval and the systolic and diastolic diameter of the left ventricle. These findings point out to an increased risk of developing arrhythmias in these patients. However, further and more complete studies should be done before recommendations about cardiologic work-up required prior infliximab therapy could be made.

Other adverse events in paediatric IBD

Recently, the case of a young Crohn's disease patient who developed a progressive multifocal leukoencephalopathy after infliximab therapy has been reported. 41 This was a 16-year-old male who presented with a sepsis following the second dose of infliximab. His clinical condition progressively deteriorated, and three months later showed MRI findings suggestive of progressive multifocal leukoencephalopathy. Neither histological specific findings nor any infectious agent could be documented. Neurological symptoms subsided, and cerebral damage disappeared six moths after infliximab discontinuation. 41

The impact of infliximab on growth retardation in children with IBD

IBD and growth

Delay in growth and puberal development is very frequent in IBD – mainly in Crohn's disease – and constitutes one of the peculiarities of this disease during this period of life. Growth retardation may occur at the time of IBD diagnosis or later, as a result of protracted chronic inflammation or its treatment. 42 , 43 If not treated before puberty, growth delay may become irreversible. About 25% of Crohn's disease and 10% of ulcerative colitis adult patients with disease onset during childhood have a height below the 5th percentile of the healthy population. 44

At the time of diagnosis, 88% of children with Crohn's disease have a delayed growth velocity, 45 and about 33% have a height below the 5th percentile. 46 In this clinical setting, the deleterious role of steroid therapy on growth is of utmost relevance. Puberty is also delayed, 47 and persists for a longer time, in those patients with Crohn's disease with continuous activity or frequent relapses in the pre-puberal period. In 73% of a series of girls with Crohn's disease starting in the pre-puberal period, menarche occurred at 16 or later. 48 Induction of clinical remission in these cases is usually followed by menarche.

The growth hormone/insulin-like growth factor-I axis

Growth hormone (GH) exerts its somatotropic actions either directly or by means of other growth factors known as insulin-like growth factor-I and II (IGF-I, IGF-II). IGFs are synthesized upon GH stimulation, mainly in the liver (thus resulting in systemic endocrine effects) but also at local level (producing paracrine/autocrine effects). IGFs circulate bound to six different IGF binding proteins (IGFBP-1 to 6) ( Fig. 4 ). IGF tissue bioavailability mostly depends on the concentrations of the different IGFBP. In general, IGFBP-3 increases the action of the IGFs, whereas it is inhibited by IGFBP-1 and 2. 49 Increased serum levels of IGFBP-2 are associated to growth retardation. 50 GH up-regulates serum IGF-1 and IGFBP-3, and down-regulates IGFBP-2. The integrity of the GH/IGF-I axis is of utmost importance for a normal growth.

Both malnutrition and pro-inflammatory cytokines negatively influence the GH/IGF-I axis ( Fig. 3 ). Malnourished children show low serum concentrations of IGF-1 which do not normalize with the administration of exogenous GH. Interleukin (IL)-1β, IL-6 and TNF-α decrease the IGF-I synthesis by blocking the GH hepatic receptors, with independence of the nutritional status. 51 Indeed serum IGF-I levels inversely correlate with the ESR, and the C-reactive protein levels, whereas IGFBP-2 are directly related to ESR, IL-1β, and IL-6. 52

In adults, it has been demonstrated that gastrointestinal inflammation – no matter what is the cause – results in decreased serum IGF-I and IGFBP-3 concentrations, as well as increased IGFBP-1 and IGFBP-2, in the presence of normal GH levels, 53 indicating the existence of peripheral resistance to GH. Similar results have been obtained in paediatric patients with active IBD. 54 , 55 These disturbances normalize upon remission.

Infliximab and the GH/IGF-I axis

The effect of infliximab on the GH/IGF-I axis has been recently assessed in a series of 14 adult IBD patients with low levels of IGF-I and IGFBP-3 treated with three induction doses (weeks 0, 2 and 6) plus two additional infusions every eight weeks. 56 Peripheral resistance to GH is apparently reversed after the second infusion of infliximab, as judged by the significant increase in the serum levels of IGF-I and IGFBP-3 as compared to baseline. However, this effect is not sustained since they return to baseline values between the first and second maintenance dose. 56 TNF blockade by infliximab could account for the initial improvement of GH sensitivity as increased TNF activity suppresses the GH/IGF-I axis in the liver. The late impairment of GH sensitivity during maintenance therapy is harder to explain, but one can speculate that during this period some degree of subclinical mucosal inflammation might persist.

Infliximab and growth catch-up in paediatric IBD

In the above-mentioned REACH trial, 15 the Z -score for height at weeks 0, 30 and 54 was assessed in those patients with more than one year retardation in their bone age (as judged by the wrist X-ray exam) ( n = 38). A significant improvement over the baseline Z -score for height was observed both at weeks 30 and 56 on infliximab therapy ( Fig. 4 ).

Borrelli et al. 57 reported on a prospective series of 18 patients (mean age: 13 years, range 6–18) with moderate-to-severe Crohn's disease refractory to conventional treatments (azathioprine/steroids), who received 5 mg/kg infliximab at weeks 0, 2 and 6 (followed in 8 of them by maintenance doses every 8 weeks). At week 8 (after the three induction doses), the PCDAI improved significantly (from 34.1 ± 5.1 to 14.8 ± 4.8; p < 0.01), as did the nutritional status and endoscopic/histological parameters. Ten patients were on clinical remission (PCDAI ≤ 10) and 12 were in endoscopic remission. All patients could discontinue steroids at week 4. At 6 months, the PCDAI was significantly lower in those patients on infliximab maintenance therapy (10.5 ± 1.41 vs. 18.8 ± 4.54 in those receiving only three induction doses; p < 0.05). By this time, significant increases in both weight and height were also observed but, again, these were much more marked in those patients receiving infliximab on a long-term basis ( Table 2 ). 57

Improving the nutritional status and promoting catch-up growth are major end-points of the treatment of paediatric IBD (mainly Crohn's disease), particularly in the pre-puberal and puberal periods. Therefore, measures of growth and development should be routinely performed during the follow-up of these patients, and failure to improve them must be considered as lack of efficacy of IBD therapy. 58 Catch-up is conceivably easier to achieve with treatments able to control mucosal inflammation and restore the nutritional status. There are reasons to believe that the growth and development of these patients is less compromised when treated with infliximab. 59 Maintenance therapy may be important in this setting.

Abbreviations

    Abbreviations
  • CDAI

    Crohn's disease activity index

  • GH

    growth hormone

  • HSTCL

    hepatosplenic T-cell lymphoma

  • IBD

    inflammatory bowel disease

  • IGF

    insulin-like growth factor

  • IGFBP

    IGF-binding protein

  • IL

    Interleukin

  • PCDAI

    paediatric Crohn's disease activity index

  • TNF

    tumour necrosis factor

References

1
Griffiths
A.M.
Enteral feeding in inflammatory bowel disease
Curr Opin Clin Nutr Metab Care
 
9
2006
314
318
2
Fell
J.M.
Paintin
M.
Arnaud-Battandier
F.
et al
Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease
Aliment Pharmacol Ther
 
14
2000
281
289
3
D'Haens
G.
Mucosal healing in pediatric Crohn's disease: the goal of medical treatment
Inflamm Bowel Dis
 
10
2004
479
480
4
Berni-Canani
R.
Terrin
G.
Borrelli
O.
et al
Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease
Dig Liver Dis
 
38
2006
381
387
5
Lionetti
P.
Bronzini
F.
Salvestrini
C.
et al
Response to infliximab is related to disease duration in paediatric Crohn's disease
Aliment Pharmacol Ther
 
18
2003
425
431
6
Kugathasan
S.
Werlin
S.L.
Martinez
A.
Rivera
M.T.
Heikenen
J.B.
Binion
D.G.
Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease
Am J Gastroenterol
 
95
2000
3189
3194
7
Bascietto
C.
De Angelis
G.L.
Bizarri
B.
Infliximab as a first-line therapy in newly diagnosed Crohn's disease (CD) promotes longterm sustained remission and alters the course of the disease
J Pediatr Gastroenterol Nutr
 
40
2005
PG2Y16
[abstract]
8
Hommes
D.
Baert
F.
Van Assche
G.
A randomized controlled trial evaluating the ideal medical management for Crohn's disease (CD): top-down vs step-up strategies
Gastroenterology
 
128
2005
A577
[abstract]
9
Vermeire
S.
van Assche
G.
Rutgeerts
P.
Review article: Altering the natural history of Crohn's disease. Evidence for and against current therapies
Aliment Pharmacol Ther
 
25
2007
3
12
10
D'Haens
G.
Van Deventer
S.
Van Hogezand
R.
et al
Endoscopic and histological healing with infliximab anti-tumour necrosis factor antibodies in Crohn's disease: a European multicenter trial
Gastroenterology
 
116
1999
1029
1034
11
Derkx
B.
Taminiau
J.
Radema
S.
et al
Tumour-necrosis-factor antibody treatment in Crohn's disease
Lancet
 
342
1993
173
174
12
Hyams
J.S.
Ferry
G.D.
Mandel
F.S.
et al
Development and validation of a pediatric Crohn's disease activity index
J Pediatr Gastroenterol Nutr
 
12
1991
439
447
13
Hyams
J.S.
Mandel
F.
Ferry
G.D.
et al
Relationship of common laboratory parameters to the activity of Crohn's disease in children
J Pediatr Gastroenterol Nutr
 
14
1992
216
222
14
de Ridder
L.
Escher
J.C.
Bouquet
J.
et al
Infliximab therapy in 30 patients with refractory pediatric Crohn disease with and without fistulas in The Netherlands
J Pediatr Gastroenterol Nutr
 
39
2004
46
52
15
Hyams
J.
Crandall
W.
Kugathasan
S.
et al
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children
Gastroenterology
 
132
2007
863
873
16
Hanauer
S.B.
Feagan
B.G.
Lichtenstein
G.R.
et al
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Lancet
 
359
2002
1541
1549
17
Ruemmele
F.M.
Infliximab: how to use it in pediatric Crohn's disease
J Pediatr Gastroenterol Nutr
 
39
2004
12
14
18
Eidelwein
A.P.
Cuffari
C.
Abadom
V.
Oliva-Hemker
M.
Infliximab efficacy in pediatric ulcerative colitis
Inflamm Bowel Dis
 
11
2005
213
218
19
Kugathasan
S.
Prajapati
D.
Kim
C.P.
Infliximab outcome in children and adults with ulcerative colitis
Gastroenterology
 
120
2001
A615
[abstract]
20
Mamula
P.
Markowitz
J.E.
Brown
K.A.
Hurd
L.B.
Piccoli
D.A.
Baldassano
R.N.
Infliximab as a novel therapy for pediatric ulcerative colitis
J Pediatr Gastroenterol Nutr
 
34
2002
307
311
21
Mamula
P.
Markowitz
J.E.
Cohen
L.J.
von Allmen
D.
Baldassano
R.N.
Infliximab in pediatric ulcerative colitis: two-year follow-up
J Pediatr Gastroenterol Nutr
 
38
2004
298
301
22
McGinnis
J.K.
Murray
K.F.
Infliximab for ulcerative colitis in children
J Pediatr Gastroenterol Nutr
 
39
Suppl. 1
2004
S282
[abstract]
23
Oliva-Hemker
M.
Roper
S.
Cuffari
C.
Leibowitz
I.
Infliximab therapy for pediatric ulcerative colitis
Gastroenterology
 
122
2002
A616
[abstract]
24
Russell
G.H.
Katz
A.J.
Infliximab is effective in acute but not chronic childhood ulcerative colitis
J Pediatr Gastroenterol Nutr
 
39
2004
166
170
25
Fanjiang
G.
Russell
G.H.
Katz
A.J.
Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis
J Pediatr Gastroenterol Nutr
 
44
2007
312
317
26
Serrano
M.S.
Schmidt-Sommerfeld
E.
Kilbaugh
T.J.
Brown
R.F.
Udall
J.N.
Mannick
E.E.
Use of infliximab in pediatric patients with inflammatory bowel disease
Ann Pharmacother
 
35
2001
823
828
27
Rutgeerts
P.
Sandborn
W.J.
Feagan
B.G.
et al
Infliximab for induction and maintenance therapy for ulcerative colitis
N Engl J Med
 
353
2005
2462
2476
28
Gisbert
J.P.
Gonzalez-Lama
Y.
Mate
J.
Systematic review: infliximab therapy in ulcerative colitis
Aliment Pharmacol Ther
 
25
2007
19
37
29
Ferrante
M.
Vermeire
S.
Katsanos
K.H.
et al
Predictors of early response to infliximab in patients with ulcerative colitis
Inflamm Bowel Dis
 
13
2007
123
128
30
Su
C.
Salzberg
B.A.
Lewis
J.D.
et al
Efficacy of anti-tumour necrosis factor therapy in patients with ulcerative colitis
Am J Gastroenterol
 
97
2002
2577
2584
31
Crandall
W.V.
Mackner
L.M.
Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model
Aliment Pharmacol Ther
 
17
2003
75
84
32
Cheifetz
A.
Smedley
M.
Martin
S.
et al
The incidence and management of infusion reactions to infliximab: a large center experience
Am J Gastroenterol
 
98
2003
1315
1324
33
Jacobstein
D.A.
Markowitz
J.E.
Kirschner
B.S.
et al
Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium
Inflamm Bowel Dis
 
11
2005
442
446
34
Mackey
A.C.
Green
L.
Liang
L.C.
Dinndorf
P.
Avigan
M.
Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease
J Pediatr Gastroenterol Nutr
 
44
2007
265
267
35
Thayu
M.
Markowitz
J.E.
Mamula
P.
Russo
P.A.
Muinos
W.I.
Baldassano
R.N.
Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn's disease
J Pediatr Gastroenterol Nutr
 
40
2005
220
222
36
Navarro
J.T.
Ribera
J.M.
Mate
J.L.
et al
Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine
Leuk Lymphoma
 
44
2003
531
533
37
Mittal
S.
Milner
B.J.
Johnston
P.W.
Culligan
D.J.
A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab
Eur J Haematol
 
76
2006
531
534
38
Van Assche
G.
D'Haens
G.
Baert
F.
et al
The clinical outcome of maintenance therapy with infliximab for luminal Crohn's disease is not affected by concomitant immunosuppressives: results of a multicenter randomized infliximab maintenance/immunosuppressives discontinuation (IMID) trial
Gastroenterology
 
128
2005
A26
[abstract]
39
Rutgeerts
P.
Van Assche
G.
Vermeire
S.
Review article: infliximab therapy for inflammatory bowel disease — seven years on
Aliment Pharmacol Ther
 
15
23
2006
451
463
40
Barbato
M.
Curione
M.
Viola
F.
et al
Cardiac involvement in children with IBD during infliximab therapy
Inflamm Bowel Dis
 
12
2006
828
829
41
Kolho
K.L.
Ruuska
T.
Savilahti
E.
Severe adverse reactions to infliximab therapy are common in young children with inflammatory bowel disease
Acta Paediatr
 
96
2007
128
130
42
Mamula
P.
Markowitz
J.E.
Baldassano
R.N.
Inflammatory bowel disease in early childhood and adolescence: special considerations
Gastroenterol Clin North Am
 
32
2003
967
995
43
Fish
D.
Kugathasan
S.
Inflammatory bowel disease
Adolesc Med Clin
 
15
2004
67
90
44
Markowitz
J.
Grancher
K.
Rosa
J.
Aiges
H.
Daum
F.
Growth failure in pediatric inflammatory bowel disease
J Pediatr Gastroenterol Nutr
 
16
1993
373
380
45
Kanof
M.E.
Lake
A.M.
Bayless
T.M.
Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease
Gastroenterology
 
95
1988
1523
1527
46
Kirschner
B.S.
Permanent growth failure in pediatric inflammatory bowel disease
J Pediatr Gastroenterol Nutr
 
16
1993
368
369
47
Brain
C.E.
Savage
M.O.
Growth and puberty in chronic inflammatory bowel disease
Baillieres Clin Gastroenterol
 
8
1994
83
100
48
Ferguson
A.
Ulcerative colitis and Crohn's disease
Br Med J
 
309
1994
355
356
49
Jones
J.I.
Clemmons
D.R.
Insulin-like growth factors and their binding proteins: biological actions
Endocr Rev
 
16
1995
3
34
50
Hoeflich
A.
Wu
M.
Mohan
S.
et al
Overexpression of insulin-like growth factor-binding protein-2 in transgenic mice reduces postnatal body weight gain
Endocrinology
 
140
1999
5488
5496
51
Thissen
J.P.
Verniers
J.
Inhibition by interleukin-1 beta and tumour necrosis factor-alpha of the insulin-like growth factor I messenger ribonucleic acid response to growth hormone in rat hepatocyte primary culture
Endocrinology
 
138
1997
1078
1084
52
Street
M.E.
de Angelis
G.
Camacho-Hubner
C.
et al
Relationships between serum IGF-1, IGFBP-2, interleukin-1beta and interleukin-6 in inflammatory bowel disease
Horm Res
 
61
2004
159
164
53
Baricevic
I.
Jones
D.R.
Nikolic
J.A.
Nedic
O.
Gastrointestinal inflammation and the circulating IGF system in humans
Horm Metab Res
 
38
2006
22
27
54
Corkins
M.R.
Gohil
A.D.
Fitzgerald
J.F.
The insulin-like growth factor axis in children with inflammatory bowel disease
J Pediatr Gastroenterol Nutr
 
36
2003
228
234
55
Wilson
D.M.
Killen
J.D.
Hammer
L.D.
et al
Insulin-like growth factor-I as a reflection of body composition, nutrition, and puberty in sixth and seventh grade girls
J Clin Endocrinol Metab
 
73
1991
907
912
56
Vespasiani-Gentilucci
U.
Caviglia
R.
Picardi
A.
et al
Infliximab reverses growth hormone resistance associated with inflammatory bowel disease
Aliment Pharmacol Ther
 
21
2005
1063
1071
[Erratum in: Aliment Pharmacol Ther 2005; 21:1398]
57
Borrelli
O.
Bascietto
C.
Viola
F.
et al
Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease
Dig Liver Dis
 
36
2004
342
347
58
Caprilli
R.
Gassull
M.A.
Escher
J.C.
et al
European Crohn's and Colitis Organisation: European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations
Gut
 
55
Suppl 1
2006
i36
i58
59
Walters
T.D.
Gilman
A.R.
Griffiths
A.M.
Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease
Inflamm Bowel Dis
 
13
2007
424
430

Figures

Figure 1

Clinical response and remission rates at week 54 in the REACH trial. 15

Figure 1

Clinical response and remission rates at week 54 in the REACH trial. 15

Figure 2

Clinical response and remission rates at week 10 in the REACH 15 and ACCENT I 16 trials.

Figure 2

Clinical response and remission rates at week 10 in the REACH 15 and ACCENT I 16 trials.

Figure 3

The GH/IGF-I axis (see text for details).

Figure 3

The GH/IGF-I axis (see text for details).

Figure 4

Changes in the mean Z -score for height in the REACH trial. 15 Mean baseline Z -score was − 1.6.

Figure 4

Changes in the mean Z -score for height in the REACH trial. 15 Mean baseline Z -score was − 1.6.

Tables

Table 1

Summary of the series assessing the efficacy of infliximab in ulcerative colitis including only paediatric patients (modified from reference # 28 )

Author (ref.) n Severity (mild/mod/severe) Indication (SD/SR)  Previous IMM ( n )  Induction doses Repeated infusions Short-term outcome Time (wk) Long-term outcome Time (mo) 
Eidelwein 18 12 0/6/6 8/4 6 (mean) Yes Response: 12/12 (100%) Response: 8/12 (67%) 10.4 
Remission: 9/12 (75%) Remission: 9/12 (75%) 
Mamula 20,21 17 1/10/6 0/17 12 Yes Response: 14/17 (82%) 0.3 Response: 10/16 (63%) 9.5 
Remission: 6/9 (66%)  
Russell 24 14 0/5/9 0/14 Yes Remission: 8/14 (57%) 2.6 Remission: 8/14 (57%) 12 
Serrano 26 – – 1–6 – Response: 3/3 (100%) – Response: 1/3 (33%) 1.5 
McGinnis 22 29 0/0/29 0/29 – – – Response: 18/29 (62%) Response: 5/29 (17%) 12 
Oliva–Hemker 23 – – Yes Response: 5/5 (100%) – – 
Remission: 2/5 (40%) 
Author (ref.) n Severity (mild/mod/severe) Indication (SD/SR)  Previous IMM ( n )  Induction doses Repeated infusions Short-term outcome Time (wk) Long-term outcome Time (mo) 
Eidelwein 18 12 0/6/6 8/4 6 (mean) Yes Response: 12/12 (100%) Response: 8/12 (67%) 10.4 
Remission: 9/12 (75%) Remission: 9/12 (75%) 
Mamula 20,21 17 1/10/6 0/17 12 Yes Response: 14/17 (82%) 0.3 Response: 10/16 (63%) 9.5 
Remission: 6/9 (66%)  
Russell 24 14 0/5/9 0/14 Yes Remission: 8/14 (57%) 2.6 Remission: 8/14 (57%) 12 
Serrano 26 – – 1–6 – Response: 3/3 (100%) – Response: 1/3 (33%) 1.5 
McGinnis 22 29 0/0/29 0/29 – – – Response: 18/29 (62%) Response: 5/29 (17%) 12 
Oliva–Hemker 23 – – Yes Response: 5/5 (100%) – – 
Remission: 2/5 (40%) 

All studies are retrospective and non-controlled series. Dose used in every study: 5 mg/kg.

SD: Steroid-dependent; SR: Steroid-refractory; IMM: immunomodulators.

Table 2

Changes in Z -scores for weight and height in paediatric Crohn's disease patients on infliximab therapy (from reference # 57 )

 Baseline At 6 moths p -value  
Patients on maintenance therapy (n = 8) 
Z -score for weight  − 0.67 ± 0.43 − 0.26 ± 0.49 < 0.01 
Z -score for height  − 1.15 ± 0.81 − 0.62 ± 0.99 < 0.01 
 
Patient receiving only three induction doses (n = 10) 
Z -score for weight  − 0.21 ± 0.44 − 0.19 ± 0.42 NS 
Z -score for height  − 0.86 ± 0.42 − 0.86 ± 0.40 NS 
 Baseline At 6 moths p -value  
Patients on maintenance therapy (n = 8) 
Z -score for weight  − 0.67 ± 0.43 − 0.26 ± 0.49 < 0.01 
Z -score for height  − 1.15 ± 0.81 − 0.62 ± 0.99 < 0.01 
 
Patient receiving only three induction doses (n = 10) 
Z -score for weight  − 0.21 ± 0.44 − 0.19 ± 0.42 NS 
Z -score for height  − 0.86 ± 0.42 − 0.86 ± 0.40 NS 

(NS: non-significant).